The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksERGO.L Regulatory News (ERGO)

  • There is currently no data for ERGO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holdings in Company

5 Feb 2018 17:07

RNS Number : 9715D
Ergomed plc
05 February 2018
 

 

For filings with the FCA include the annex

For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Ergomed Plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Slater Investments Ltd

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

06th February 2018

6. Date on which issuer notified:

05th February 2018

7. Threshold(s) that is/are crossed orreached: vi, vii

Above 10%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

 

 

GB00BN7ZCY67

4,129,000

9.67%

161,000

161,000

4,308,000

0.36%

9.64%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

4,469,000

10.00%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

14. Contact name:

Ralph Baber

15. Contact telephone number:

+ 44 20 7220 9460

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLTAMRTMBMMBAP
Date   Source Headline
26th Apr 20189:58 amRNSIssue of shares and PDMR
17th Apr 20185:47 pmRNSHoldings in Company
16th Apr 20183:55 pmRNSDirectors' Dealing
11th Apr 20187:00 amRNSPreliminary Results
9th Apr 20186:26 pmRNSHolding(s) in Company
20th Mar 20187:00 amRNSNotice of Preliminary Results: Date Change
5th Mar 20187:00 amRNSTrading Update & Notice of Results
21st Feb 20182:35 pmRNSHoldings in Company
6th Feb 20182:03 pmRNSHoldings in Company
5th Feb 20185:07 pmRNSHoldings in Company
1st Feb 20189:39 amRNSDirectors' Dealing
1st Feb 20187:00 amRNSCompletion of Placing
25th Jan 20187:00 amRNSErgomed 2017 Trading Update
10th Jan 20181:00 pmRNSHoldings in Company
15th Dec 20177:00 amRNSBoard changes
12th Dec 20177:00 amRNSCo-dev partnership with Allergy Therapeutics
4th Dec 20177:00 amRNSErgomed's PrimeVigilance hosts automation seminar
27th Nov 20177:00 amRNSErgomed to present at the German Equity Forum 2017
23rd Oct 20177:00 amRNSErgomed's PeproStat reports positive results
12th Oct 20174:48 pmRNSHolding(s) in Company
3rd Oct 20177:00 amRNSCompletion of Acquisition of PSR Group BV
28th Sep 201710:46 amRNSResult of Placing
28th Sep 20177:02 amRNSAcquisition of PSR Group BV and Placing
27th Sep 20177:00 amRNSCommercialisation Deal on Haemostatix Products
18th Sep 20177:00 amRNSInterim Results
21st Aug 20177:06 amRNSCEL-SCI Corporation issues restricted shares
14th Aug 201712:31 pmRNSFDA removal of hold on Ph3 trial with Multikine
14th Aug 20177:00 amRNSNotice of Results
24th Jul 20177:00 amRNSRecruitment complete early for Phase IIb study
4th Jul 201712:30 pmRNSInvestor Meeting
21st Jun 20177:00 amRNSPeproStat study passes recruitment mid-point
16th Jun 20175:44 pmRNSResult of AGM
16th Jun 20177:00 amRNSAppointment of CEO
22nd May 20177:00 amRNSAppointment of N+1 Singer as joint broker
12th May 20174:54 pmRNSAnnual Report and Notice of AGM
8th May 201712:00 pmRNSIssue of Shares to Former PharmInvent Shareholders
2nd May 20177:00 amRNSCo-Development Partner News
13th Apr 20177:00 amRNSBoard and Management Changes
4th Apr 201710:50 amRNSDirector/PDMR Shareholding
3rd Apr 20177:00 amRNSPartner Asarina Pharma announces successful data
28th Mar 20177:00 amRNSUnaudited Preliminary Results for 2016
21st Mar 20177:00 amRNSNotice of Preliminary Results
20th Mar 20177:00 amRNSInitiates Phase II Study of Topical PeproStat
20th Feb 20177:00 amRNSModus Therapeutics Raises SEK 32 Million
6th Feb 20177:02 amRNSPositive Phase II top-line results of Lorediplon
31st Jan 20174:00 pmRNSCompletion of ZoptrexT Phase 3 Clinical Trial
17th Jan 20177:00 amRNSTrading Statement
30th Nov 20164:35 pmRNSAward of Options by CEO to CFO and General Counsel
29th Nov 20167:00 amRNSAcquisition of PharmInvent
21st Nov 20167:00 amRNSProposed Board Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.